RE:RE:Low volumeI kind of feel like a savant today. Everything I said was odd yesterday is now been fulfilled today. Analyst upgrades and volume. Still they need to be on the Nasdaq for that $50/shr price. Read an article yesterday that the Nasdaq is slammed with biotech companies wanting to get listed.
This company is UNDERVALUED but is not liquid enough. They may want to consider a stock split or Share Dividends not cash.